Humana (NYSE:HUM) Stock Rating Lowered by Zacks Research

Humana (NYSE:HUM) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Humana’s Q1 2027 earnings at $9.04 EPS.

Several other analysts also recently issued reports on HUM. Needham & Company LLC began coverage on Humana in a research note on Wednesday, May 20th. They issued a “buy” rating on the stock. UBS Group initiated coverage on Humana in a report on Thursday, July 30th. They set a “buy” rating for the company. Royal Bank Of Canada lifted their target price on Humana from $246.00 to $415.00 and gave the company a “sector perform” rating in a research report on Thursday, July 9th. Seaport Research Partners downgraded Humana to a “neutral” rating in a research report on Wednesday, May 20th. Finally, Guggenheim raised their price target on shares of Humana from $269.00 to $471.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $395.22.

Humana Stock Up 4.3%

Humana stock opened at $388.86 on Tuesday. The company has a 50 day moving average of $380.56 and a 200-day moving average of $274.05. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62. Humana has a twelve month low of $163.11 and a twelve month high of $428.88. The stock has a market capitalization of $46.69 billion, a PE ratio of 36.79, a price-to-earnings-growth ratio of 2.13 and a beta of 0.72.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts’ consensus estimates of $7.27 by $0.34. The business had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. The firm’s quarterly revenue was up 26.2% on a year-over-year basis. During the same period last year, the business posted $6.27 earnings per share. On average, equities research analysts anticipate that Humana will post 9.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Humana

A number of institutional investors and hedge funds have recently made changes to their positions in HUM. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Humana in the second quarter valued at $19,277,000. Barrow Hanley Mewhinney & Strauss LLC bought a new stake in Humana during the second quarter worth $314,922,000. Bank of Nova Scotia acquired a new stake in Humana in the second quarter valued at $102,314,000. Compass Financial Management LLC bought a new position in shares of Humana in the 2nd quarter valued at about $1,229,000. Finally, Daiichi Life Insurance Co. Ltd. acquired a new position in shares of Humana during the 2nd quarter worth about $980,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.